Under terms of the agreement, ImprimisRx to assume full responsibility for US sales and marketing activities for Dexycu.
EyePoint Pharmaceuticals Inc. and ImprimisRx this week jointly announced the expansion of their commercial alliance in which ImprimisRx will assume responsibility for U.S. sales and marketing activities for dexamethasone intraocular suspension 9% (Dexycu) for the treatment of post-operative inflammation following ocular surgery in the U.S.
The amended agreement expands the commercial alliance previously established in August 2020 between the companies.
“EyePoint is excited to build upon our successful collaboration with ImprimisRx to promote awareness and demand for Dexycu to cataract surgeons and patients in need of more effective treatments to manage ocular inflammation following surgery,” Scott Jones, chief commercial officer of EyePoint Pharmaceuticals, said in a statement. “We are dedicated to providing long-lasting solutions to all patients suffering from ophthalmic diseases. This expanded partnership enables us to fully leverage ImprimisRx’s presence and tremendous expertise in ocular and cataract surgery, while allowing EyePoint to focus our efforts on advancing our retinal disease-focused pipeline. We look forward to working closely with the ImprimisRx team to accelerate Dexycu’s growth, bringing its many benefits to more physicians and patients.”
John Saharek, president of ImprimisRx, said the company is pleased to expand its partnership with EyePoint to continue to bring dexamethasone intraocular suspension 9%, an FDA-approved injectable steroid product, to patients experiencing inflammation following ocular surgery.
“A growing number of our ophthalmologist customers experience the benefits Dexycu offers as a sustained release treatment option that is a complement to their patients’ eye drop regimen,” he said in a statement. “We are pleased with the success we have had thus far in building customer demand for Dexycu, which we expect to grow as result of the expansion of our partnership with EyePoint. We look forward to executing our U.S. commercial strategy alongside EyePoint to attain our shared goal of even greater success for many years to come.”
Under the terms of the expanded commercial alliance, ImprimisRx will assume responsibility for the sales and marketing of dexamethasone intraocular suspension 9% in the U.S. and will absorb the majority of EyePoint’s dexamethasone intraocular suspension 9% commercial organization. EyePoint will continue to recognize net product revenue and maintain manufacturing and distribution responsibilities for dexamethasone intraocular suspension 9% along with non-sales related regulatory compliance. EyePoint will pay ImprimisRx a commission based on the net sales of dexamethasone intraocular suspension 9% and will retain all commercial rights for dexamethasone intraocular suspension 9%.
This amended agreement will be effective on January 1, 2022.